COVID-19 Test Uses `Lab at Your Fingertip` Technology to Measure SARS-CoV-2 Antibodies in 15 Minutes
By LabMedica International staff writers Posted on 10 Dec 2020 |
Image: ADEXUSDx® COVID-19 Test (Photo courtesy of NOWDiagnostics, Inc.)
A new rapid serology, self-contained assay uses "lab at your fingertip" technology to accurately measure the presence of SARS-CoV-2 antibodies in 15 minutes with no buffers, reagents, or additional equipment.
The ADEXUSDx COVID-19 antibody test from NOWDiagnostics, Inc. (Springdale, AR, USA) is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies and delivers lab-quality results in 15 minutes with no buffers, reagents, or additional equipment. The test requires only a drop of blood (either capillary blood from a simple fingerstick or 40 μL of venous whole blood, serum, or plasma) and has the potential to be deployed directly into homes and workplaces. The ADEXUSDx COVID-19 antibody test can be used across a variety of health care settings - from hospital emergency rooms to clinics - and ultimately, by consumers for at-home use.
The innovative diagnostic device delivered 100% sensitivity and 100% specificity in a well-characterized 45 sample panel of COVID-19 positive and negative patient samples, and was filed for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). If FDA authorizes emergency use, the ADEXUSDx COVID-19 Test will become available for use in CLIA-certified laboratories across a variety of health care settings from clinics to hospital emergency rooms in the US.
Related Links:
NOWDiagnostics, Inc.
The ADEXUSDx COVID-19 antibody test from NOWDiagnostics, Inc. (Springdale, AR, USA) is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies and delivers lab-quality results in 15 minutes with no buffers, reagents, or additional equipment. The test requires only a drop of blood (either capillary blood from a simple fingerstick or 40 μL of venous whole blood, serum, or plasma) and has the potential to be deployed directly into homes and workplaces. The ADEXUSDx COVID-19 antibody test can be used across a variety of health care settings - from hospital emergency rooms to clinics - and ultimately, by consumers for at-home use.
The innovative diagnostic device delivered 100% sensitivity and 100% specificity in a well-characterized 45 sample panel of COVID-19 positive and negative patient samples, and was filed for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). If FDA authorizes emergency use, the ADEXUSDx COVID-19 Test will become available for use in CLIA-certified laboratories across a variety of health care settings from clinics to hospital emergency rooms in the US.
Related Links:
NOWDiagnostics, Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants